Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice

E. Racila, R. H. Scheuermann, Louis Picker, E. Yefenof, T. Tucker, W. Chang, R. Marches, N. E. Street, E. S. Vitetta, J. W. Uhr

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Tumor dormancy can be induced in a murine B cell lymphoma (BCL1) by immunizing BALB/c mice with the tumor immunoglobulin (Ig) before tumor cell challenge. In this report, we have investigated the immunological and cellular mechanisms underlying the induction of dormancy. BCL1 tumor cells were injected into SCID mice passively immunized with antibody against different epitopes on IgM or IgD with or without idiotype (Id)-immune T lymphocytes. Results indicate that antibody to IgM is sufficient to induce a state of dormancy. Antibodies against other cell surface molecules including IgD and CD44 (Pgp1) had no effect on tumor growth. Id-immune T cells by themselves also had no effect on tumor growth in SCID mice. However, simultaneous transfer of anti-Id and Id-immune T cells enhanced both the induction and duration of the dormant state. In vitro studies indicated that antibody to IgM induced apoptosis within several hours and cell cycle arrest by 24 h. Hyper cross-linking increased apoptosis. The FcγRII receptor played little or no role in the negative signaling. Antibodies that did not negatively signal in vitro did not induce dormancy in vivo. The results suggest that anti-IgM plays a decisive role in inducing tumor dormancy to BCL1 by acting as an agonist of IgM-mediated signal transduction pathways.

Original languageEnglish (US)
Pages (from-to)1539-1550
Number of pages12
JournalJournal of Experimental Medicine
Volume181
Issue number4
DOIs
StatePublished - Apr 1 1995
Externally publishedYes

Fingerprint

SCID Mice
B-Cell Lymphoma
Antibodies
Immunoglobulin M
Neoplasms
Immunoglobulin D
T-Lymphocytes
Apoptosis
Growth
Cell Cycle Checkpoints
Immunoglobulins
Epitopes
Signal Transduction

ASJC Scopus subject areas

  • Immunology

Cite this

Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice. / Racila, E.; Scheuermann, R. H.; Picker, Louis; Yefenof, E.; Tucker, T.; Chang, W.; Marches, R.; Street, N. E.; Vitetta, E. S.; Uhr, J. W.

In: Journal of Experimental Medicine, Vol. 181, No. 4, 01.04.1995, p. 1539-1550.

Research output: Contribution to journalArticle

Racila, E, Scheuermann, RH, Picker, L, Yefenof, E, Tucker, T, Chang, W, Marches, R, Street, NE, Vitetta, ES & Uhr, JW 1995, 'Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice', Journal of Experimental Medicine, vol. 181, no. 4, pp. 1539-1550. https://doi.org/10.1084/jem.181.4.1539
Racila, E. ; Scheuermann, R. H. ; Picker, Louis ; Yefenof, E. ; Tucker, T. ; Chang, W. ; Marches, R. ; Street, N. E. ; Vitetta, E. S. ; Uhr, J. W. / Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice. In: Journal of Experimental Medicine. 1995 ; Vol. 181, No. 4. pp. 1539-1550.
@article{212117d5b7194215ba8d81962a6c5695,
title = "Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice",
abstract = "Tumor dormancy can be induced in a murine B cell lymphoma (BCL1) by immunizing BALB/c mice with the tumor immunoglobulin (Ig) before tumor cell challenge. In this report, we have investigated the immunological and cellular mechanisms underlying the induction of dormancy. BCL1 tumor cells were injected into SCID mice passively immunized with antibody against different epitopes on IgM or IgD with or without idiotype (Id)-immune T lymphocytes. Results indicate that antibody to IgM is sufficient to induce a state of dormancy. Antibodies against other cell surface molecules including IgD and CD44 (Pgp1) had no effect on tumor growth. Id-immune T cells by themselves also had no effect on tumor growth in SCID mice. However, simultaneous transfer of anti-Id and Id-immune T cells enhanced both the induction and duration of the dormant state. In vitro studies indicated that antibody to IgM induced apoptosis within several hours and cell cycle arrest by 24 h. Hyper cross-linking increased apoptosis. The FcγRII receptor played little or no role in the negative signaling. Antibodies that did not negatively signal in vitro did not induce dormancy in vivo. The results suggest that anti-IgM plays a decisive role in inducing tumor dormancy to BCL1 by acting as an agonist of IgM-mediated signal transduction pathways.",
author = "E. Racila and Scheuermann, {R. H.} and Louis Picker and E. Yefenof and T. Tucker and W. Chang and R. Marches and Street, {N. E.} and Vitetta, {E. S.} and Uhr, {J. W.}",
year = "1995",
month = "4",
day = "1",
doi = "10.1084/jem.181.4.1539",
language = "English (US)",
volume = "181",
pages = "1539--1550",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "4",

}

TY - JOUR

T1 - Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice

AU - Racila, E.

AU - Scheuermann, R. H.

AU - Picker, Louis

AU - Yefenof, E.

AU - Tucker, T.

AU - Chang, W.

AU - Marches, R.

AU - Street, N. E.

AU - Vitetta, E. S.

AU - Uhr, J. W.

PY - 1995/4/1

Y1 - 1995/4/1

N2 - Tumor dormancy can be induced in a murine B cell lymphoma (BCL1) by immunizing BALB/c mice with the tumor immunoglobulin (Ig) before tumor cell challenge. In this report, we have investigated the immunological and cellular mechanisms underlying the induction of dormancy. BCL1 tumor cells were injected into SCID mice passively immunized with antibody against different epitopes on IgM or IgD with or without idiotype (Id)-immune T lymphocytes. Results indicate that antibody to IgM is sufficient to induce a state of dormancy. Antibodies against other cell surface molecules including IgD and CD44 (Pgp1) had no effect on tumor growth. Id-immune T cells by themselves also had no effect on tumor growth in SCID mice. However, simultaneous transfer of anti-Id and Id-immune T cells enhanced both the induction and duration of the dormant state. In vitro studies indicated that antibody to IgM induced apoptosis within several hours and cell cycle arrest by 24 h. Hyper cross-linking increased apoptosis. The FcγRII receptor played little or no role in the negative signaling. Antibodies that did not negatively signal in vitro did not induce dormancy in vivo. The results suggest that anti-IgM plays a decisive role in inducing tumor dormancy to BCL1 by acting as an agonist of IgM-mediated signal transduction pathways.

AB - Tumor dormancy can be induced in a murine B cell lymphoma (BCL1) by immunizing BALB/c mice with the tumor immunoglobulin (Ig) before tumor cell challenge. In this report, we have investigated the immunological and cellular mechanisms underlying the induction of dormancy. BCL1 tumor cells were injected into SCID mice passively immunized with antibody against different epitopes on IgM or IgD with or without idiotype (Id)-immune T lymphocytes. Results indicate that antibody to IgM is sufficient to induce a state of dormancy. Antibodies against other cell surface molecules including IgD and CD44 (Pgp1) had no effect on tumor growth. Id-immune T cells by themselves also had no effect on tumor growth in SCID mice. However, simultaneous transfer of anti-Id and Id-immune T cells enhanced both the induction and duration of the dormant state. In vitro studies indicated that antibody to IgM induced apoptosis within several hours and cell cycle arrest by 24 h. Hyper cross-linking increased apoptosis. The FcγRII receptor played little or no role in the negative signaling. Antibodies that did not negatively signal in vitro did not induce dormancy in vivo. The results suggest that anti-IgM plays a decisive role in inducing tumor dormancy to BCL1 by acting as an agonist of IgM-mediated signal transduction pathways.

UR - http://www.scopus.com/inward/record.url?scp=0028968004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028968004&partnerID=8YFLogxK

U2 - 10.1084/jem.181.4.1539

DO - 10.1084/jem.181.4.1539

M3 - Article

C2 - 7535341

AN - SCOPUS:0028968004

VL - 181

SP - 1539

EP - 1550

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 4

ER -